GALLANT-1: Galectin-3 (Gal-3) inhibitor, GB1211, plus atezolizumab (atz) in patients (pts) with non-small cell lung cancer (NSCLC) - a dose finding study followed by a randomised, double-blind, placebo-controlled trial

被引：1

作者：

Ghiringhelli, F. ^{[1
]}

Barre, P. ^{[2
]}

Pichon, E. ^{[3
]}

Aix, S. Ponce ^{[4
]}

Vidal, O. J. Juan ^{[5
]}

Costa, E. Carcereny ^{[6
]}

Sethi, T. ^{[7
]}

Lindmark, B. ^{[8
]}

MacKinnon, A. ^{[7
]}

Aslanis, V. ^{[9
]}

Phung, D. H. ^{[10
]}

Jensen, P. ^{[11
]}

Rajiwate, Z. ^{[12
]}

Ross, G. ^{[8
]}

Basse, L. ^{[8
]}

机构：

[1] Univ Burgundy, Genet & Immuno therapy Med Inst, Ctr Georges Francois Leclerc, Dijon, France

[2] Montpellier Reg Univ Hosp, Dept Thorac Oncol, Montpellier, France

[3] CHRU Bretonneau, Serv Pneumol, Tours, France

[4] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[5] La Fe Univ Hosp, Dept Med Oncol, Valencia, Spain

[6] Germans Trias & Pujol Hosp, Catalan Inst Oncol Badalona, Dept Med Oncol, Barcelona, Spain

[7] Galecto Biotech AB, Pre Clin Res & Dev, Copenhagen, Denmark

[8] Galecto Biotech AB, Clin Res & Dev, Copenhagen, Denmark

[9] Galecto Biotech AB, Pharmacokinet, Copenhagen, Denmark

[10] Galecto Biotech AB, Biostat, Copenhagen, Denmark

[11] Galecto Biotech AB, Project Management, Copenhagen, Denmark

[12] Galecto Biotech AB, Clin Operat, Copenhagen, Denmark

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1315

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1192TiP

引用

页码：S1093 / S1094

页数：2

共 50 条

[41] The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design
Coats, Andrew J. Stewart
Srinivasan, Venkatesan
Surendran, Jayaraman
Chiramana, Haritha
Vangipuram, Shankar R. K. G.
Bhatt, Nirajkumar N.
Jain, Minish
Shah, Sandip
Ali, Irfhan A. B. H.
Fuang, Ho G.
Hassan, Mohammed Z. M.
Beadle, John
Tilson, Julia
Kirwan, Bridget-Anne
Anker, Stefan D.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2011, 2 (04) : 201 - 207
[42] Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study
Han, Baohui
Li, Kai
Wang, Qiming
Zhao, Yizhuo
Zhang, Li
Shi, Jianhua
Wang, Zhehai
Cheng, Yin
He, Jianxing
Shi, Yuankai
Chen, Weiqiang
Wang, Xiuwen
Luo, Yi
Nan, Kejun
Jin, Faguang
Li, Baolan
Chen, Yinlan
Zhou, Jianying
Wang, Donglin
LANCET ONCOLOGY, 2017, 18 : S3 - S3
[43] The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC).
Spigel, David R.
Edelman, Martin J.
Mok, Tony
O'Byrne, Kenneth John
Paz-Ares, Luis
Yu, Wei
Rittweger, Karen
Thurm, Holger C.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[44] Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial
Heymach, John, V
Mitsudomi, Tetsuya
Harpole, David
Aperghis, Mike
Jones, Stephanie
Mann, Helen
Fouad, Tamer M.
Reck, Martin
CLINICAL LUNG CANCER, 2022, 23 (03) : E247 - E251
[45] BEYOND: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE III STUDY OF FIRST-LINE CARBOPLATIN/PACLITAXEL (CP) PLUS BEVACIZUMAB (BV) OR PLACEBO (PL) IN CHINESE PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Zhou, Caicun
Chen, Gongyan
Liu, Xiaoqing
Zhu, Yunzhong
Lu, Shun
Feng, Jifeng
He, Jianxing
Han, Baohui
Wang, Jie
Jiang, Guoliang
Hu, Chunhong
Zhang, Hao
Cheng, Gang
Song, Xiangqun
Lu, You
Pan, Hongming
Zheng, Wenjuan
Yin, Anny-Yue
Wu, Yi-Long
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S293 - S293
[46] International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1
Scagliotti, Giorgio V.
Vynnychenko, Ihor
Park, Keunchil
Ichinose, Yukito
Kubota, Kaoru
Blackhall, Fiona
Pirker, Robert
Galiulin, Rinat
Ciuleanu, Tudor-Eliade
Sydorenko, Oleksandr
Dediu, Mircea
Papai-Szekely, Zsolt
Martinez Banaclocha, Natividad
McCoy, Sheryl
Yao, Bin
Hei, Yong-jiang
Galimi, Francesco
Spigel, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (23) : 2829 - 2836
[47] Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study
Vansteenkiste, Johan
Zielinksi, Marcin
Linder, Albert
Dahabre, Jubrail
Esteban, Emilio
Malinowski, Wojciech
Jassem, Jacek
Passlick, Bernward
Lehmann, Frederic
Brichard, Vincent G.
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S334 - S335
[48] A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)
Jatoi, Aminah
Ritter, Howard L.
Dueck, Amylou
Nguyen, Phuong L.
Nikcevich, Daniel A.
Luyun, Ronnie F.
Mattar, Bassam I.
Loprinzi, Charles L.
LUNG CANCER, 2010, 68 (02) : 234 - 239
[49] BIOMARKER ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF ERLOTINIB WITH AND WITHOUT ENTINOSTAT, A CLASS 1 ISOFORM SELECTIVE HISTONE DEACETYLASE INHIBITOR (HDAC) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC; ENCORE-401)
Jotte, Robert
Witta, Samir
Neubauer, Marcus
Spira, Alexander
Ruxer, Robert
Konduri, Kartik
Hirsch, Fred R.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S607 - S608
[50] A randomized, double-blind, placebo-controlled phase II study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer (NSCLC).
Von Pawel, Joachim
Hadler, Dietrich
Fox, Tara
Wang, Qiang
Greenberg, Jonathan
Beckman, Robert A.
Krzakowski, Maciej Jerzy
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →